pantoprazole has been researched along with Indigestion in 37 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the safety and efficacy of fixed-dose combination tablets of naproxen/esomeprazole magnesium and nimesulide/pantoprazole to determine if both regimens are equally suited to relieve pain in patients with osteoarticular diseases and dyspeptic symptoms." | 9.27 | Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. ( Amazonas, RB; Bocchi de Oliveira, MF; Ecclissato, C; Macêdo, EA; Pott Júnior, H; Scheinberg, M, 2018) |
| "To assess the efficacy of adjunctive therapy with curcumin on the eradication of Helicobacter pylori infection and severity of dyspepsia in patients with PU." | 9.22 | Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. ( Biglarian, O; Ghamarchehreh, ME; Khonche, A; Majeed, M; Panahi, Y; Sahebkar, A; Soflaei, SS; Valizadegan, G, 2016) |
| "In this double-blind, placebo-controlled, multicentre study, patients experiencing ulcer-like functional dyspepsia, with epigastric pain as the predominant symptom, were randomised to receive pantoprazole 20 mg or placebo o." | 9.13 | Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. ( Berghöfer, P; Dattani, ID; Enns, R; Fischer, R; Gonzalez Carro, P; Maritz, JF; Schwan, T; van Rensburg, C, 2008) |
| " pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 9.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
| "The study was designed to detect novel Adverse Events (AEs) of pantoprazole by disproportionality analysis in the FDA (Food and Drug Administration) database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs)." | 5.91 | Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database. ( Eswaran, M; Kulkarni, AR; Nair, HP; Subeesh, V, 2023) |
| "This study investigated the safety and efficacy of fixed-dose combination tablets of naproxen/esomeprazole magnesium and nimesulide/pantoprazole to determine if both regimens are equally suited to relieve pain in patients with osteoarticular diseases and dyspeptic symptoms." | 5.27 | Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. ( Amazonas, RB; Bocchi de Oliveira, MF; Ecclissato, C; Macêdo, EA; Pott Júnior, H; Scheinberg, M, 2018) |
| "To assess the efficacy of adjunctive therapy with curcumin on the eradication of Helicobacter pylori infection and severity of dyspepsia in patients with PU." | 5.22 | Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. ( Biglarian, O; Ghamarchehreh, ME; Khonche, A; Majeed, M; Panahi, Y; Sahebkar, A; Soflaei, SS; Valizadegan, G, 2016) |
| "In this double-blind, placebo-controlled, multicentre study, patients experiencing ulcer-like functional dyspepsia, with epigastric pain as the predominant symptom, were randomised to receive pantoprazole 20 mg or placebo o." | 5.13 | Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. ( Berghöfer, P; Dattani, ID; Enns, R; Fischer, R; Gonzalez Carro, P; Maritz, JF; Schwan, T; van Rensburg, C, 2008) |
| " pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b." | 5.11 | Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. ( Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z, 2004) |
| " pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 5.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
| "Non-ulcer dyspepsia patients (n=199), with a normal upper endoscopy and a positive (13)C-urea breath test (UBT) were randomly assigned to either pantoprazole, clarithromycin and metronidazole (PCM) or pantoprazole, clarithromycin and eicosapen (PCE) for 7 days." | 5.09 | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. ( Drewe, J; Geiser, HR; Meier, R; Wettstein, A, 2001) |
| "In functional dyspepsia, pantoprazole influenced the acid-induced duodenogastric feedback mechanism, but not the impaired duodenal motor response." | 5.09 | Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia. ( Samsom, M; Schwartz, MP; Smout, AJ; Van Berge Henegouwen, GP, 2001) |
| "pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd." | 5.08 | [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995) |
| " In the first stage, the efficacy of 4-week pantoprazole treatment was compared with placebo in patients with uninvestigated dyspepsia." | 3.81 | Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. ( Arabacı, E; Baysal, B; Buğdacı, MS; İnce, AT; Kayar, Y; Masri, O; Şentürk, H; Tozlu, M; Uysal, Ö, 2015) |
| "Halitosis was significantly more prevalent in the group of patients with persistent H." | 2.80 | Eradication of gastric Helicobacter pylori ameliorates halitosis and tongue coating. ( Bojic, B; Milasin, J; Popovic, B; Zaric, S, 2015) |
| "GORD patients who after long-term continuous treatment were able to use less than a daily PPI dose in a placebo-controlled trial were compared to patients who persisted in a daily dosage with respect to general, lifestyle and quality of life characteristics (SF-36 Health Survey) as well as psychological factors (Symptom Check List 90), symptom control on daily PPI (Quality of Life in Reflux and Dyspepsia questionnaire), disease and medication history." | 2.78 | Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error. ( de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2013) |
| "Gastro-oesophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are highly prevalent gastrointestinal conditions with accumulating evidence of overlap in patients." | 2.77 | Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. ( Lühmann, R; Mönnikes, H; Sander, P; Schwan, T; Straszak, A; Theek, C; van Rensburg, C, 2012) |
| " Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0." | 2.71 | Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. ( Biagini, R; Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansi, C; Mele, MR; Savarino, V; Tessieri, L; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "The study was designed to detect novel Adverse Events (AEs) of pantoprazole by disproportionality analysis in the FDA (Food and Drug Administration) database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs)." | 1.91 | Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database. ( Eswaran, M; Kulkarni, AR; Nair, HP; Subeesh, V, 2023) |
| " However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy." | 1.36 | Editorial: just how "difficult" is it to withdraw PPI treatment? ( Howden, CW; Kahrilas, PJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (16.22) | 18.2507 |
| 2000's | 16 (43.24) | 29.6817 |
| 2010's | 13 (35.14) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Nair, HP | 1 |
| Kulkarni, AR | 1 |
| Eswaran, M | 1 |
| Subeesh, V | 1 |
| Wauters, L | 1 |
| Ceulemans, M | 1 |
| Frings, D | 1 |
| Lambaerts, M | 1 |
| Accarie, A | 1 |
| Toth, J | 1 |
| Mols, R | 1 |
| Augustijns, P | 1 |
| De Hertogh, G | 1 |
| Van Oudenhove, L | 1 |
| Tack, J | 1 |
| Vanuytsel, T | 1 |
| Scheinberg, M | 1 |
| Pott Júnior, H | 1 |
| Macêdo, EA | 1 |
| Bocchi de Oliveira, MF | 1 |
| Ecclissato, C | 1 |
| Amazonas, RB | 1 |
| Mönnikes, H | 2 |
| Schwan, T | 3 |
| van Rensburg, C | 3 |
| Straszak, A | 2 |
| Theek, C | 2 |
| Lühmann, R | 2 |
| Sander, P | 2 |
| Tholen, A | 1 |
| Baysal, B | 1 |
| Şentürk, H | 1 |
| Masri, O | 1 |
| Tozlu, M | 1 |
| Kayar, Y | 1 |
| Arabacı, E | 1 |
| Uysal, Ö | 1 |
| Buğdacı, MS | 1 |
| İnce, AT | 1 |
| Zaric, S | 1 |
| Bojic, B | 1 |
| Popovic, B | 1 |
| Milasin, J | 1 |
| Chan, CC | 1 |
| Chien, NH | 1 |
| Lee, CL | 1 |
| Yang, YC | 1 |
| Hung, CS | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Khonche, A | 1 |
| Biglarian, O | 1 |
| Panahi, Y | 1 |
| Valizadegan, G | 1 |
| Soflaei, SS | 1 |
| Ghamarchehreh, ME | 1 |
| Majeed, M | 1 |
| Sahebkar, A | 1 |
| Berghöfer, P | 1 |
| Enns, R | 1 |
| Dattani, ID | 1 |
| Maritz, JF | 1 |
| Gonzalez Carro, P | 1 |
| Fischer, R | 1 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Pellicano, R | 1 |
| Demir, M | 1 |
| Gokturk, HS | 1 |
| Ozturk, NA | 1 |
| Serin, E | 1 |
| Yilmaz, U | 1 |
| Niklasson, A | 1 |
| Lindström, L | 1 |
| Simrén, M | 1 |
| Lindberg, G | 1 |
| Björnsson, E | 2 |
| Howden, CW | 1 |
| Kahrilas, PJ | 1 |
| Quasdorff, M | 1 |
| Mertens, J | 1 |
| Dinter, J | 1 |
| Steffen, HM | 1 |
| Musikatavorn, K | 1 |
| Tansangngam, P | 1 |
| Lumlertgul, S | 1 |
| Komindr, A | 1 |
| van der Velden, AW | 1 |
| de Wit, NJ | 1 |
| Quartero, AO | 1 |
| Grobbee, DE | 1 |
| Numans, ME | 1 |
| Armstrong, D | 1 |
| Kazim, F | 1 |
| Gervais, M | 1 |
| Pyzyk, M | 1 |
| Boixeda, D | 1 |
| Bermejo, F | 1 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 1 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Dulbecco, P | 1 |
| Gambaro, C | 1 |
| Bilardi, C | 1 |
| Zentilin, P | 1 |
| Mele, MR | 1 |
| Mansi, C | 1 |
| Biagini, R | 1 |
| Tessieri, L | 1 |
| Iiritano, E | 1 |
| Usai, P | 1 |
| Vigneri, S | 1 |
| Savarino, V | 1 |
| Buzás, GM | 1 |
| Uygun, A | 2 |
| Kadayifçi, A | 2 |
| Yeşilova, Z | 2 |
| Savaş, MC | 1 |
| Ateş, Y | 1 |
| Karslioğlu, Y | 1 |
| Ciğerim, M | 1 |
| Bağci, S | 1 |
| Dağalp, K | 1 |
| Geevasinga, N | 1 |
| Coleman, PL | 1 |
| Webster, AC | 1 |
| Roger, SD | 1 |
| Sezgin, O | 2 |
| Altintaş, E | 2 |
| Uçbilek, E | 2 |
| Tataroğlu, C | 1 |
| Tombak, A | 1 |
| Tellioğlu, B | 1 |
| Safali, M | 1 |
| Ilgan, S | 1 |
| Karaeren, N | 1 |
| Labenz, J | 1 |
| Peitz, U | 1 |
| Tillenburg, B | 1 |
| Becker, T | 1 |
| Börsch, G | 1 |
| Stolte, M | 1 |
| Lamers, CB | 1 |
| Adamek, RJ | 2 |
| Szymanski, C | 2 |
| Pfaffenbach, B | 2 |
| Améndola, R | 1 |
| Roldán, CD | 1 |
| Morgade, L | 1 |
| Solagna, A | 1 |
| Lineado, A | 1 |
| Musi, AO | 1 |
| Valero, J | 1 |
| Zerbo, O | 1 |
| Kogan, Z | 1 |
| Ferro, FE | 1 |
| Schenone, L | 1 |
| Corti, R | 1 |
| Lamouliatte, H | 2 |
| Samoyeau, R | 2 |
| De Mascarel, A | 2 |
| Megraud, F | 2 |
| Broutet, N | 1 |
| Marais, A | 1 |
| Salamon, R | 1 |
| Meier, R | 1 |
| Wettstein, A | 1 |
| Drewe, J | 1 |
| Geiser, HR | 1 |
| Schwartz, MP | 1 |
| Samsom, M | 1 |
| Van Berge Henegouwen, GP | 1 |
| Smout, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients[NCT03545243] | Phase 4 | 79 participants (Actual) | Interventional | 2018-04-23 | Completed | ||
| Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients.[NCT01670552] | Phase 3 | 490 participants (Actual) | Interventional | 2016-02-17 | Completed | ||
| CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD[NCT00325676] | Phase 4 | 639 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain[NCT01281501] | Phase 4 | 87 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Non-responders defined the participants who had < 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores > 40 at the end of the study." (NCT01281501)
Timeframe: pretreatment and 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 8 |
| Pantoprazole | 11 |
"Responders define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study." (NCT01281501)
Timeframe: pretreatment and 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 36 |
| Pantoprazole | 32 |
The satisfaction will be assessed by a simple, self-reported yes/no question. (NCT01281501)
Timeframe: 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 34 |
| Pantoprazole | 34 |
"Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment. Minimal and maximal VAS score of every measurement is 0 to 100 millimeters. VAS scores at 1 hour after treatment were the primary outcome measurement. The patients who had <50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores > 40 millimeters were defined as Non-responders(worse outcome). In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as Responders (good outcome)." (NCT01281501)
Timeframe: 1 hour after treatment
| Intervention | millimeter (Mean) |
|---|---|
| Conventional | 17 |
| Pantoprazole | 19 |
2 reviews available for pantoprazole and Indigestion
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
The changing role of H2-receptor antagonists in acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1996 |
23 trials available for pantoprazole and Indigestion
| Article | Year |
|---|---|
Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Dysp | 2018 |
Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastro | 2013 |
Eradication of gastric Helicobacter pylori ameliorates halitosis and tongue coating.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2015 |
Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2016 |
Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Anti-Ulcer Agents; | 2008 |
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2009 |
Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Chromogranin A; Double-Blind Method; Dyspepsia | 2010 |
A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Pain; Adult; Anti-Ulcer Agents; Double-Blind Method; | 2012 |
Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dyspepsia; Female; Gastroesophageal Reflux; Humans; | 2012 |
Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; He | 2013 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Breath Tests; Dose-Response Relations | 2003 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infect | 2006 |
Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2007 |
Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benz | 2001 |
Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chemoreceptor Cel | 2001 |
12 other studies available for pantoprazole and Indigestion
| Article | Year |
|---|---|
Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Dyspepsia; | 2023 |
Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.
Topics: Adult; Belgium; Bile Acids and Salts; Case-Control Studies; Duodenal Diseases; Duodenum; Dyspepsia; | 2021 |
Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Editorial: just how "difficult" is it to withdraw PPI treatment?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophagitis; Gastric Acid; Gastroesophageal Refl | 2010 |
It is difficult to discontinue PPI treatment in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Esophagitis; Gastric A | 2011 |
Recurrent hypomagnesemia with proton-pump inhibitor rechallenge.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dyspepsia; Female; Humans; Hypocalcemia; Magnesium; | 2011 |
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Canad | 2002 |
[The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
Proton pump inhibitors and acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Kidney Injury; Adult; Age Distribution; Aged; Aged, 8 | 2006 |
[Is dental plaque a normal Helicobacter pylori reservoir?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Benzimidazoles; Clari | 1998 |